Early effect of hyaluronic acid intra-articular injections on serum and urine biomarkers in patients with knee osteoarthritis: An open-label observational prospective study

Journal of Orthopaedic Research

Volumn 30, Issue 5, 2012, Pages 679-685

  Conrozier, Thierry ^a   Balblanc, Jean Charles ^b   Richette, Pascal ^c   Mulleman, Denis ^d   Maillet, Bernard ^e   Henrotin, Yves ^f   Rannou, Francois ^g   Piroth, Catherine ^h,l   Hilliquin, Pascal ⁱ   Mathieu, Pierre ^a   Walliser Lohse, Anne ^b   Rousselot, Isabelle ^j   Plattner, Valerie ^k   Maillefert, Jean Francis ^h   Vignon, Eric ^a   Chevalier, Xavier ^m  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b Rheumatology   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITÉ DE TOURS   (France)

^e Clinique StOdilon   (France)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g Institut Cochin   (France)

^h DIJON UNIVERSITY HOSPITAL   (France)

ⁱ CENTRE HOSPITALIER SUD FRANCILIEN   (France)

^j Synarc Lyon   (France)

^k HOSPICES CIVILS DE LYON   (France)

^l UNIVERSITÉ DE BOURGOGNE   (France)

^m HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

biomarkers; hyaluronic acid; hylan; knee; osteoarthritis

Indexed keywords

BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; CARTILAGE OLIGOMERIC MATRIX PROTEIN; COLLAGEN TYPE 2; CREATININE; HYALURONIC ACID;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EXAMINATION; COLLAGEN DEGRADATION; CORRELATION COEFFICIENT; CREATININE URINE LEVEL; DRUG EFFECT; FEMALE; HUMAN; KNEE OSTEOARTHRITIS; LOGISTIC REGRESSION ANALYSIS; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; URINALYSIS; VISCOSUPPLEMENTATION; VISUAL ANALOG SCALE; X RAY;

AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PROSPECTIVE STUDIES; VISCOSUPPLEMENTATION; VISCOSUPPLEMENTS;

EID: 84858276425     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21580     Document Type: Article

References (52)

1. Felson DT,. 2003. The epidemiology osteoarthritis. In:, Brandt KD, Doherty M, Lohmander LS, editors. Osteoarthritis. Oxford, England: Oxford University Press: p 9-16.
2. Le Pen C, Reygrobellet C, Gerentes I,. 2005. Financial cost of osteoarthritis in France. The "COART" France study. Joint Bone Spine 72: 567-570. (Pubitemid 41821418)
3. American College of Rheumatology subcommittee on osteoarthritis guidelines. 2000. Recommendations for the medical management of osteoarthritis of the hip and the knee. 2000 update. Arthritis Rheum 43: 1905-1915.
4. Zhang W, Doherty M, Peat G, et al. 2010. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis 69: 483-489.
5. Zhang W, Nuki G, Moskowitz RW, et al. 2010. OARSI recommendations for the management of hip and knee osteoarthritis: Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cart 18: 476-499.
6. Waddell DD,. 2007. Viscosupplementation with hyaluronans for osteoarthritis of the knee: clinical efficacy and economic implications. Drugs Aging 24: 629-642. (Pubitemid 47294712)
7. Balazs EA, Denlinger JL,. 1993. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl 9: 3-9. (Pubitemid 23284286)
8. Balazs EA,. 2004. Viscosupplementation for treatment of osteoarthritis: from initial discovery to current status and results. Surg Technol Int 12: 278-289.
9. Bagga H, Burkhardt D, Sambrook P, et al. 2006. Long-term effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol 33: 946-950.
10. Balazs EA,. 2003. Analgesic effect of elastoviscous hyaluronan solutions and the treatment of arthritic pain. Cells Tissues Organs 174: 49-62. (Pubitemid 36677093)
11. Gomis A, Miralles A, Schmidt RF, et al. 2007. Nociceptive nerve activity in an experimental model of knee joint osteoarthritis of the guinea pig: Effect of intra-articular hyaluronan application. Pain 130: 126-136. (Pubitemid 46850785)
12. Waddell DD, Kolomytkin OV, Dunn S, et al. 2007. Hyaluronan suppresses IL-1beta-induced metalloproteinase activity from synovial tissue. Clin Orthop Relat Res 465: 241-248. (Pubitemid 350306523)
13. Ghosh P, Guidolin D,. 2002. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum 32: 10-37. (Pubitemid 35001162)
14. Goto M, Hanyu T, Yoshio T, et al. 2001. Intra-articular injection of hyaluronate (SI-6601D) improves joint pain and synovial fluid prostaglandin E2 levels in rheumatoid arthritis: a multicenter clinical trial. Clin Exp Rheumatol 19: 377-383. (Pubitemid 32685364)
15. Yatabe T, Mochizuki S, Takizawa M, et al. 2009. Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes. Ann Rheum Dis 68: 1051-1058.
16. Greenberg DD, Stoker A, Kane S, et al. 2006. Biochemical effects of two different hyaluronic acid products in a co-culture model of osteoarthritis. Osteoarthritis Cart 14: 814-822. (Pubitemid 43986363)
17. Grishko V, Xu M, Ho R, et al. 2010. Effects of hyaluronic acid on mitochondrial function and mitochondria-driven apoptosis following oxidative stress in human chondrocytes. J Biol Chem 18: 284.
18. Conrozier T, Mathieu P, Schott AM, et al. 2003. Factors predicting long-term efficacy of Hylan GF-20 viscosupplementation in knee osteoarthritis. Joint Bone Spine 70: 128-133. (Pubitemid 36528287)
19. Qvist P, Christiansen C, Karsdal MA, et al. 2010. Application of biochemical markers in development of drugs for treatment of osteoarthritis. Biomarkers 15: 1-19.
20. van Spil WE, DeGroot J, Lems WF, et al. 2010. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthritis Cart 18: 605-612.
21. Henrotin Y, Addison S, Kraus V, et al. 2007. Type II collagen markers in osteoarthritis-what do they indicate? Current Opin Rheumatol 19: 444-450. (Pubitemid 47344236)
22. Verstappen SM, Poole AR, Ionescu M, et al. 2006. Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther 8: R31.
23. Conrozier T, Ferrand F, Poole AR, et al. 2007. Differences in biomarkers of type II collagen in atrophic and hypertrophic osteoarthritis of the hip: implications for the differing pathobiologies. Osteoarthritis Cartilage 15: 462-467. (Pubitemid 46381560)
24. Sharif M, Kirwan J, Charni N, et al. 2007. A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis-association with disease progression. Rheumatology 46: 938-943. (Pubitemid 47062500)
25. Garnero P, Conrozier T, Christgau S, et al. 2003. Urinary type II collagen C-telopeptide levels are increased in patients with rapidly destructive hip osteoarthritis. Ann Rheum Dis 62: 939-943. (Pubitemid 37159491)
26. Garnero P, Ayral X, Rousseau JC, et al. 2002. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 46: 2613-2624. (Pubitemid 36118924)
27. Sugiyama S, Itokazu M, Suzuki Y, et al. 2003. Procollagen II C propeptide level in the synovial fluid as a predictor of radiographic progression in early knee osteoarthritis. Ann Rheum Dis 62: 27-32. (Pubitemid 36005791)
28. Otterness IG, Swindell AC, Zimmerer RO, et al. 2000. An analysis of 14 molecular markers for monitoring osteoarthritis: segregation of the markers into clusters and distinguishing osteoarthritis at baseline. Osteoarthritis Cartilage 8: 180-185. (Pubitemid 30304185)
29. Poole AR, Ionescu M, Swan A, et al. 1994. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis. J Clin Invest 94: 25-33.
30. Sharif M, Saxne T, Shepstone L, et al. 1995. Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. Br J Rheumatol 34: 306-310.
31. Conrozier T, Saxne T, Fan CS, et al. 1998. Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: a one year prospective study. Ann Rheum Dis 57: 527-532. (Pubitemid 28474059)
32. Sharif M, George E, Shepstone L, et al. 1995. Serum hyaluronic acid level as a predictor of disease progression in osteoarthritis of the knee. Arthritis Rheum 38: 760-767.
33. Goldberg RL, Huff JP, Lenz ME, et al. 1991. Elevated plasma levels of hyaluronate in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 34: 799-807.
34. Altman R, Asch E, Bloch D, et al. 1986. Development of criteria for the classification and reporting of osteoarthritis. Arthritis Rheum 29: 1039-1049.
35. Kellgren JH, Lawrence JS,. 1957. Radiographic assessment of osteoarthritis. Ann Rheum Dis 6: 494-502.
36. Kong SY, Stabler TV, Criscione LG, et al. 2006. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum 54: 2496-2504. (Pubitemid 44205010)
37. Christgau S, Garnero P, Fledelius C, et al. 2001. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 29: 209-215. (Pubitemid 32823562)
38. Lehmann HJ, Mouritzen U, Christgau S, et al. 2002. Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis 61: 530-533. (Pubitemid 34539098)
39. Hedbom E, Antonsson P, Hjerpe A, et al. 1992. Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem 267: 6132-6136.
40. Garnero P, Piperno M, Gineyts E, et al. 2001. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 60: 619-626. (Pubitemid 32493990)
41. Nelson F, Dahlberg L, Laverty S, et al. 1998. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 102: 2115-2125. (Pubitemid 29018818)
42. Briot K, Roux C, Gossec L, et al. 2008. Effects of etanercept on serum biochemical markers of cartilage metabolism in patients with spondyloarthropathy. Br J Rheumatol 35: 310-314. (Pubitemid 351281153)
43. Billinghurst RC, Dahlberg L, Ionescu M, et al. 1997. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 99: 1534-1545. (Pubitemid 27163804)
44. Poole AR, Ionescu M, Fitzcharles MA, et al. 2004. The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by the collagenases. J Immunol Methods 294: 145-153. (Pubitemid 39626599)
45. Glant TT, Mikecz PJ, Roughley PJ, et al. 1986. Age related changes in protein-related epitopes of human articular cartilage proteoglycans. Biochem J 236: 71-75. (Pubitemid 16095514)
46. Mazzuca SA, Poole AR, Brandt KD, et al. 2006. Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis. J Rheumatol 33: 1147-1151. (Pubitemid 43825469)
47. Cibere J, Zhang H, Garnero P, et al. 2009. Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthritis Rheum 60: 1372-1380.
48. Bingham CO, Buckland-Wright JC, Garnero P, et al. 2006. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 54: 3494-3507. (Pubitemid 44737161)
49. Bay-Jensen AC, Andersen TL, Charni-Ben Tabassi N, et al. 2008. Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage. Osteoarthritis Cartilage 16: 615-623. (Pubitemid 351545558)
50. Shimizu M, Higuchi H, Takagishi K, et al. 2010. Clinical and biochemical characteristics after intra-articular injection for the treatment of osteoarthritis of the knee: prospective randomized study of sodium hyaluronate and corticosteroid. J Orthop Sci 15: 51-56.
51. Anandacoomarasamy A, Bagga H, Ding C, et al. 2008. Predictors of clinical response to intraarticular Hylan injections-a prospective study using synovial fluid measures, clinical outcomes, and magnetic resonance imaging. J Rheumatol 35: 685-690. (Pubitemid 351500067)
52. Sugimoto H, Yamada H, Terada N, et al. 2006. Intraarticular injection of high molecular weight hyaluronan for osteoarthritis of the knee-prediction of effectiveness with biological markers. J Rheumatol 33: 2527.